PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Volatility and Risk
PROCEPT BioRobotics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500.
Valuation & Earnings
This table compares PROCEPT BioRobotics and Sight Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PROCEPT BioRobotics | $308.05 million | 4.17 | -$95.57 million | ($1.82) | -12.40 |
| Sight Sciences | $77.36 million | 4.00 | -$38.43 million | ($0.71) | -8.01 |
Sight Sciences has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares PROCEPT BioRobotics and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PROCEPT BioRobotics | -31.82% | -27.70% | -20.29% |
| Sight Sciences | -46.83% | -52.34% | -28.49% |
Institutional & Insider Ownership
89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 30.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and price targets for PROCEPT BioRobotics and Sight Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PROCEPT BioRobotics | 2 | 5 | 7 | 1 | 2.47 |
| Sight Sciences | 1 | 3 | 5 | 0 | 2.44 |
PROCEPT BioRobotics presently has a consensus target price of $40.42, suggesting a potential upside of 79.15%. Sight Sciences has a consensus target price of $8.14, suggesting a potential upside of 43.12%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Sight Sciences.
Summary
PROCEPT BioRobotics beats Sight Sciences on 10 of the 15 factors compared between the two stocks.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
